Nhua Pharmaceutical disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 3.218 billion yuan, up 6.91% year on year. Net profit attributable to shareholders of the listed company was 741 million yuan, up 5.74% year on year. Net profit attributable to shareholders after deducting non-recurring items was 746 million yuan, up 6.65% year on year. By business segment, anesthetic products generated revenue of 1.668 billion yuan, up 2.08% year on year. Psychiatric products generated revenue of 651 million yuan, up 4.88% year on year. Neurological product revenue reached 222 million yuan, up 33.70% year on year, making it the fastest-growing core business segment in the first half. Commercial pharmaceutical business revenue in the same period reached 461 million yuan, up 17.20% year on year. The company invested 385 million yuan in research and development in the first half, with more than 70 projects under study, including over 20 innovative drug projects and more than 40 key generic drug projects, while also carrying out 5 consistency evaluation projects. Its self-developed Class 1 innovative drug NH600001 emulsion injection has been submitted for marketing approval and passed the registration inspection by the National Medical Products Administration. The Class 1 innovative drug NHL35700 for schizophrenia entered Phase III clinical trials in June this year. NH102 tablets, YH1910-Z02 injection, and YH1910-Z01 nasal spray have completed Phase II clinical studies, and NH130 tablets are currently undergoing Phase II clinical research. The company has also established an AI-driven research and development team and is laying out antibody-oligonucleotide conjugate technology. Its investee company Jiangsu Haoxinqing's internet hospital has registered more than 80,000 doctors. The C-BCT digital cognitive assessment product of its controlling subsidiary Beijing Yihua has established cooperation with more than 100 medical institutions and has served over 300,000 patient visits cumulatively.
Jiangsu Nhwa Pharmaceutical Co LtdFirst-half revenue and profit grew, with neurological product revenue up 33.70%.
